Skip to content

    Marksans Pharma

    MARKSANS
    Healthcare·27 May 2026
    Management Summary

    Marksans Pharma delivered a strong Q4 and FY26, achieving its highest-ever profitability with FY26 operating revenue of INR2,951 crores and an EBITDA margin of 20.4%. The company reported robust growth across key geographies, particularly North America and Australia, and remains debt-free with substantial cash reserves. While anticipating raw material cost inflation and rising logistics costs in Q1 FY27, management reaffirmed its target of INR4,000 crores revenue by FY28 and is actively pursuing M&A opportunities to drive future growth.

    Highlights

    7

    • FY26 operating revenue of INR2,951 crores, up 12.5% YoY, marking the first time crossing INR3,000 crores in net income (as stated by management).

    • FY26 EBITDA margin expanded to 20.4%, driven by better product mix and operating leverage.

    • Q4 FY26 EBITDA margin was particularly strong at 22.8%, expanding by 491 bps YoY.

    • North America FY26 revenue grew 24% YoY to INR1,533 crores, demonstrating scalability and strong customer relationships.

    • Q4 UK & EU revenue reached an all-time quarterly high of INR308 crores, representing a 12.3% YoY growth.

    • Australia & New Zealand Q4 revenue grew 61.3% YoY to INR123 crores, with entry into branded prescription generics.

    • Company is debt-free with a robust cash and cash equivalent balance of INR990 crores as of March 31, 2026.

    Concerns

    3

    • Raw material cost inflation of 20-30% on petroleum-related materials is expected to impact Q1 FY27 margins.

    • Logistics costs are creeping up by approximately 2%, though currently not alarming.

    • Geopolitical uncertainties create a lack of clarity for contract renegotiations, with management preferring to 'wait and watch'.

    Key financials

    Metrics

    14

    Periods

    2

    Q4 FY26

    5
    • Operating Revenue
      ₹856 Cr
      YoY+20.8%
    • EBITDA
      ₹195 Cr
      YoY+54%
    • EBITDA Margin
      22.8%
    • PAT
      ₹149 Cr
      YoY+64.3%
    • EPS
      ₹3.3

    FY26

    9
    • Operating Revenue
      ₹2,951 Cr
      YoY+12.5%
    • EBITDA
      ₹601 Cr
    • EBITDA Margin
      20.4%
    • PAT
      ₹420 Cr
    • EPS
      ₹9.2

    Segment breakdown

    North America (FY26)
    ₹1,533 Cr40.5%
    UK & EU (FY26)
    ₹1,015 Cr26.8%
    North America (Q4 FY26)
    ₹406 Cr10.7%
    UK & EU (Q4 FY26)
    ₹308 Cr8.1%
    Australia & New Zealand (FY26)
    ₹303 Cr8.0%
    Australia & New Zealand (Q4 FY26)
    ₹123 Cr3.2%
    Rest of World (FY26)
    ₹99 Cr2.6%
    Treemap· Share of Revenue

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Dividend

    ₹0.9/share (final)

    Payout ratio 90.0%

    M&A

    Deal

    acquisition · announced · Consideration ₹NaN (undisclosed)

    Liquidity

    Cash ₹990 crores

    Provides substantial flexibility to invest in future growth opportunities.

    Guidance & targets

    9
    CategoryTargetPriority
    Revenue
    Total Revenue
    INR4,000 crores
    		High
    Revenue
    Total Revenue
    Double revenue
    		High
    Revenue
    Australia Revenue
    $100 million
    		High
    Revenue
    Canada Revenue Contribution
    small part trickling in
    		Medium
    Revenue
    Europe Revenue Contribution
    some results
    		Medium
    Pipeline
    New Products in US
    50-odd products
    		High
    Margin
    EBITDA Margin
    20-21%
    		High
    Revenue Growth
    Top-line Growth
    15-20%
    		Medium
    R&D Spend
    R&D Spend as % of Revenue
    3%
    		High

    Q1 FY27 Margin Impact from RM Costs

    next quarter
    CurrentExpected inflationary pressure on RM costs in Q1 FY27
    TargetVerify if Q1 FY27 margins are impacted as anticipated

    Why it matters

    Direct impact on profitability and a key concern raised by management for the upcoming quarter.

    We expect obviously some inflationary pressure on raw materials costs during Q1 FY27 due to the ongoing geopolitical and supply chain disruption.

    How to verify

    key_financials.metrics[label='EBITDA Margin']

    Risks & concerns

    3
    RiskSeverity

    Raw material cost inflation

    20-30% price escalation on petroleum-related raw materials expected to impact Q1 FY27, though mitigated by inventory and forex. — Management acknowledged

    high

    Logistics cost increase

    Logistics costs are creeping up by ~2%, but not yet alarming. — Management acknowledged

    medium

    Geopolitical uncertainty impacting contract renegotiations

    Lack of clarity on war resolution makes customers hesitant to renegotiate contracts, but force majeure is an option if prolonged. — Management acknowledged

    medium

    Q&A highlights

    8

    “So we are witnessing obviously, raw materials which directly or indirectly have petroleum-related ingredients or intermediates involved in that. So we are seeing a price escalation of over 20% to 30% on these raw materials. That said and done, we are presently having a decent amount of inventory of raw materials.”

    Analyst probed on the impact of rising raw material costs on profitability, and management acknowledged the inflation but indicated mitigation through inventory and forex benefits.

    asked by Ahmed Madha

    2 min read6 chapters

    Detailed Narrative

    01

    Strong FY26 Performance and Profitability Milestones

    Marksans Pharma achieved a significant milestone in FY26, with operating revenue reaching INR2,951 crores, marking a 12.5% year-on-year growth. The company reported its highest-ever profitability, with Profit After Tax (PAT) of INR420 crores and an EPS of INR9.2. The EBITDA margin expanded to 20.4% for the full year, demonstrating strong operational efficiency and improved product mix.

    02

    Robust Q4 Momentum Across Key Geographies

    The fourth quarter of FY26 showcased strong performance, with operating revenue at INR856 crores, a 20.8% increase year-on-year. Q4 EBITDA margin was particularly strong at 22.8%, expanding by 491 basis points compared to the previous year. North America revenue grew 23.6% YoY to INR406 crores, while UK and EU revenue reached an all-time quarterly high of INR308 crores, up 12.3% YoY. Australia and New Zealand also contributed significantly, with Q4 revenue growing 61.3% YoY to INR123 crores.

    03

    Strategic Expansion and Product Pipeline Development

    Marksans Pharma is actively expanding its global footprint, having entered new markets such as Germany, Canada, and Ireland, and strengthening its presence in Australia through branded prescription generics. The company launched 112 SKUs in FY26 and has a robust pipeline, with 51 additional products in North America and an expected increase of 50-odd products for the US in 2026-27. The Teva facility is currently operating at close to 50% utilization, with significant scope for 40-50% growth.

    04

    Capital Allocation Focused on Growth and Shareholder Returns

    The company maintains a strong financial position, ending FY26 debt-free with a cash and cash equivalent balance of INR990 crores as of March 31, 2026. This liquidity provides flexibility for future growth investments. The Board recommended a final dividend of INR0.90 per equity share, representing a 90% payout on face value for FY26. Marksans is also actively pursuing M&A opportunities, with two targets in dialogue and one undergoing due diligence, anticipating transactions in 2027.

    05

    Navigating Raw Material and Logistics Headwinds

    Management acknowledged potential raw material cost inflation of 20-30% on petroleum-related ingredients, which could impact Q1 FY27 margins. However, the company has mitigated this risk by maintaining 5-6 months of inventory and benefiting from favorable forex movements. Logistics costs are also observed to be creeping up by approximately 2%, though currently not considered alarming. Geopolitical uncertainties are causing a 'wait and watch' approach for contract renegotiations.

    06

    Long-term Vision and Market Outlook

    Marksans Pharma is confident in achieving INR4,000 crores in revenue by FY28 and aims to double its revenue within the next 3 to 5 years. The company projects a top-line growth of 15-20% for FY27 and expects to maintain its EBITDA margins in the 20-21% range. The Australian market is targeted to reach $100 million in revenue within the next three years, with Canada and Europe expected to contribute to revenue towards the end of FY26 and in H2 FY26, respectively.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.